SRT1720 activates AMPK by directly inhibiting cAMP phosphodiesterases, suggesting that cAMP phosphodiesterases may be potential drug targets for obesity-related diseases. Here, PRKAA1 is linked to obesity due to melanocortin 4 receptor deficiency.